Brokerages expect that Incyte Co. (NASDAQ:INCY) will report earnings per share (EPS) of ($0.47) for the current fiscal quarter, Zacks Investment Research reports. Twenty analysts have made estimates for Incyte’s earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at $0.09. Incyte reported earnings per share of $0.15 in the same quarter last year, which would suggest a negative year-over-year growth rate of 413.3%. The business is expected to report its next quarterly earnings results before the market opens on Thursday, February 15th.
According to Zacks, analysts expect that Incyte will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.49) to ($1.00). For the next year, analysts anticipate that the business will post earnings of $0.13 per share, with EPS estimates ranging from ($1.83) to $1.98. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Incyte.
INCY has been the topic of a number of analyst reports. BMO Capital Markets decreased their target price on shares of Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a report on Thursday, October 26th. Royal Bank of Canada decreased their target price on shares of Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 21st. Oppenheimer set a $135.00 target price on shares of Incyte and gave the stock a “hold” rating in a report on Tuesday, October 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, October 31st. Finally, Deutsche Bank initiated coverage on shares of Incyte in a report on Tuesday, December 12th. They set a “hold” rating and a $106.00 target price on the stock. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Incyte currently has a consensus rating of “Buy” and a consensus price target of $143.25.
In other news, Director Paul A. Friedman sold 28,507 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the completion of the sale, the insider now directly owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The disclosure for this sale can be found here. Insiders sold a total of 40,963 shares of company stock worth $4,222,953 in the last three months. Insiders own 17.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Nordea Investment Management AB boosted its stake in shares of Incyte by 0.8% in the 2nd quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 67 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Incyte by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 108 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Incyte by 1.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,571 shares of the biopharmaceutical company’s stock valued at $953,000 after purchasing an additional 143 shares in the last quarter. AMP Capital Investors Ltd boosted its stake in shares of Incyte by 0.7% in the 3rd quarter. AMP Capital Investors Ltd now owns 72,076 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 500 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in shares of Incyte by 2.8% in the 3rd quarter. Amalgamated Bank now owns 20,332 shares of the biopharmaceutical company’s stock valued at $2,374,000 after purchasing an additional 561 shares in the last quarter. 90.36% of the stock is owned by institutional investors.
Incyte (NASDAQ INCY) traded up $0.41 during midday trading on Friday, hitting $86.33. 202,859 shares of the stock traded hands, compared to its average volume of 1,731,032. Incyte has a one year low of $85.75 and a one year high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $18,240.00, a price-to-earnings ratio of -107.85 and a beta of 0.59.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Incyte Co. (INCY) to Announce -$0.47 Earnings Per Share” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thestockobserver.com/2018/02/05/analysts-anticipate-incyte-co-incy-to-announce-0-47-earnings-per-share.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.